Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-01-30
2010-11-23
Martinell, James (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100
Reexamination Certificate
active
07838234
ABSTRACT:
Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor. Further described are kits and indications that are optionally used in conjunction with the aforementioned methods and compositions.
REFERENCES:
patent: 2003/0166026 (2003-09-01), Goodman
patent: 1400806 (2004-03-01), None
patent: 1426054 (2004-06-01), None
patent: 1595952 (2005-11-01), None
patent: WO 2005-059108 (2005-06-01), None
LePage, C. et al., “From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer,” Int. J. Cancer 118(7):1750-1758 (2006).
Natrajan, R. et al., “Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse,” J. Pathol. 210(1):49-58 (2006).
PCT/US08/52540 Search Report dated Jun. 17, 2008.
Hardiman, “Microarray Platforms-Comparisons and Contrasts,” Pharmacogenomics 5(5):487-502 (20040.
Piekarz et al. “T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance,” Blood 103(12):4636-4643 (2004).
Sasakawa et al., “Marker genes to predict sensitivity to FK 228, a histone deacetylase inhibitor,” Biochem. Pharmacol. 69(4):603-616 (2005).
EP 08728620 Supplementary Search Report mailed Aug. 24, 2010.
Balasubramanian Sriram
Buggy Joseph J.
Martinell James
Pharmacyclics Inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Methods for determining cancer resistance to histone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for determining cancer resistance to histone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for determining cancer resistance to histone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4165840